Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Partial Onset Seizures Clear all
Completed Phase 3 Interventional Results available

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT02072824
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 3 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Orlando, Florida • Tampa, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT02535091
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Jul 23, 2026, 12:46 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539
View directory record Official record
Conditions
Refractory Partial Onset Seizures
Interventions
Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

NCT01284556
View directory record Official record
Conditions
Epilepsy
Interventions
Phenobarbital, Placebo tablet
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
17 Years to 70 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

NCT01397968
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
16
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

NCT00938431
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
14
States / cities
Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT01338805
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 66 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional Results available

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

NCT00152451
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (ucb 44212)
Drug
Lead sponsor
UCB S.A. - Pharma Sector
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 23, 2026, 12:46 AM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 23, 2026, 12:46 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Xcopri
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 12:46 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0600

NCT00512317
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 23, 2026, 12:46 AM EDT
Terminated Phase 4 Interventional Results available

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346
View directory record Official record
Conditions
Epilepsy
Interventions
ezogabine/retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Bethesda, Maryland • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00735397
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 23, 2026, 12:46 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

NCT01721317
View directory record Official record
Conditions
Seizures
Interventions
Ezogabine/Retigabine IR, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
9
States / cities
Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Jul 23, 2026, 12:46 AM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Port Charlotte, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

NCT01964560
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 23, 2026, 12:46 AM EDT
Terminated Not applicable Interventional

RNS System RESPONSE Study

NCT04839601
View directory record Official record
Conditions
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Grand Rapids, Michigan • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

NCT01261325
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 80 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 12:46 AM EDT
Completed Phase 2 Interventional

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

NCT00105040
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo (PB)
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Jul 23, 2026, 12:46 AM EDT